Ocular Surface Changes in Prostaglandin Analogue-Treated Patients

Glaucoma is the second leading cause of blindness globally. Reducing intraocular pressure (IOP) has been acknowledged to be the main therapy for glaucoma. Prostaglandin analogues (PGAs) have become the first-line therapy for patients with glaucoma due to their powerful efficacy for lowering (IOP). H...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Wencui, Huang, Bingqing, Yang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925925/
https://www.ncbi.nlm.nih.gov/pubmed/31885896
http://dx.doi.org/10.1155/2019/9798272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925925/
https://www.ncbi.nlm.nih.gov/pubmed/31885896
http://dx.doi.org/10.1155/2019/9798272

Ejemplares similares